Prof Zamagni is Associate Professor of Hematology at the Bologna University, Italy. She received her medical degree from University of Bologna, where she also served her residency in hematology. She completed her PhD in clinical hematology at the University of Bologna in May 2005. Her research interests include areas related to multiple myeloma (MM), in particular on the role of high-dose therapy with stem cell support, prognostic factors, minimal residual disease and imaging techniques.

She has published over 150 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She has contributed to the educational session of the Italian Society of Haematology (SIE) and American Society of Clinical Oncology. She is an abstract reviewer for the SIE, European Hematology Association (EHA) and American Society of Hematology. She is part of the editorial board of several hematological journals. She is an active board member of the Italian group, GIMEMA, and the European Myeloma Network working party. She has cooperated in the scientific secretary and as principal investigator in several national and international randomized trials in MM. She is a member of the SIE, International Myeloma Working Group, and International Myeloma Society (IMS). She has served on the EHA’s Scientific Program Committee from 2017 to 2022, and has been responsible for the career development committee within the IMS since 2019. Prof Zamagni has been a member of the IMS board since 2023 as
a representative for Europe.